Phaseline

Companies › Accro Bioscience (Suzhou)

Accro Bioscience (Suzhou): clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Immunology, Other; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AC-101–Phase 2Ulcerative Colitis (UC); Ulcerative ColitisNov 2027
AC-003–Phase 1Acute Graft-versus-Host Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07083193AC-101Phase 1Ulcerative ColitisImmunologyApr 2026
NCT07070674AC-003Phase 1Acute Graft-versus-Host DiseaseOtherSep 2026
NCT07755241AC-101Phase 2Ulcerative Colitis (UC)ImmunologyNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Clarent Biopharma Mirador Therapeutics Shattuck Labs Astria Therapeutics Daewon Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.